The Week in Blood Pressure & Wearables — September 4-10, 2026
Six industry alerts, two newsletters, and one theme kept surfacing this week: getting paid for remote monitoring is no longer something companies can take for granted. Medicare's 2027 fee schedule proposal targets how outsourced monitoring gets billed. An independent assessment found that virtual kidney care vendors cannot show their programs change outcomes. And a landmark hypertension trial out of rural China delivered blood pressure control its biggest headline in years: a 15 percent drop in dementia risk over seven years.
Here is our roundup of the blood pressure and wearable health technology news that mattered from September 4 to September 10, 2026, organized by devices and wearables, policy and regulation, and clinical research, plus a deep dive into the Medicare proposal that could reshape who gets paid to monitor patients at home.
Devices & Wearables
Sky Labs brings new clinical data on its cuffless BP ring to ESC Congress. Sky Labs presented new clinical data on its CART ring at the European Society of Cardiology Congress in Munich, across five separate sessions (PR Newswire). CART is a ring-type blood pressure monitor that estimates blood pressure without a cuff, using photoplethysmography (PPG) sensors on the finger combined with an AI algorithm, the same optical approach used for wearable heart rate and oxygen tracking, adapted here to estimate blood pressure (Vietnam Investment Review).
In one study, the device tracked 24-hour blood pressure in atrial fibrillation patients, a population where irregular heartbeats typically confuse standard oscillometric cuffs, and returned usable data about 80 percent of the time. In a second study of heart failure patients with severely reduced heart function, CART readings closely tracked conventional ambulatory blood pressure monitoring and met European Society of Hypertension accuracy standards for cuffless devices.
CART is now recommended in South Korea's 2026 hypertension guidelines, described as a first for a ring-type cuffless monitor, and has been prescribed more than 300,000 times across over 2,000 Korean medical institutions. This week's release did not include an update on CE marking or FDA clearance status, and we will not guess at either until Sky Labs confirms them directly.
Apple Watch Series 12 and Ultra 4 push heart rate sensing further, not blood pressure. Apple began preorders for the Watch Series 12 and Watch Ultra 4 this week, both built around what Apple calls its most accurate heart rate sensing yet in a wearable (Apple Newsroom). The new Health Sensing System uses redesigned optical (PPG) sensors to take heart rate readings roughly every five seconds and expands heart rate variability tracking into a new daytime Vitals metric and readiness score (Ars Technica).
Apple has not added blood pressure measurement to either watch. The upgrade matters to Cardiowell's world mainly as a signal: the world's largest wearable maker keeps investing in higher-fidelity heart rate sensing, the same underlying signal cuffless blood pressure researchers, including Sky Labs and Oura, are trying to extend into blood pressure estimation.
Oura files for a $16 billion IPO, and confirms it is chasing cuffless blood pressure too. Oura filed for an IPO this week, targeting a Nasdaq listing at roughly $16 billion (Tech Times). The company reported $1.2 billion in revenue for the nine months ending June 2026, 5 million paying subscribers, and 55 percent gross margins, a striking scale for a company built around a single PPG sensor in a ring.
Oura does not currently measure blood pressure. The company disclosed it is running an investigational blood pressure study enrolling more than 350,000 participants, aimed at eventually offering blood pressure trend signals from the same optical sensor it uses for heart rate and HRV. If that study holds up and clears FDA review, it puts another major consumer wearable maker on the same cuffless blood pressure path several device makers are now pursuing, each with different sensors, different validation data, and different regulatory timelines worth checking one by one rather than assuming they are all making the same claim.
Policy & Regulation
Medicare's 2027 proposal would rewrite who gets paid to run RPM programs. The single most important story for Cardiowell this week did not involve a device launch. It involved a spreadsheet full of billing codes.
CMS's proposed 2027 Medicare Physician Fee Schedule would change the rules for who gets paid to run remote patient monitoring (RPM) programs (HIT Consultant). The proposal would limit reimbursement for the actual clinical monitoring work, reviewing readings and following up with patients, to staff directly employed by the billing practice rather than outsourced to a third-party vendor. It would require an initiating in-person visit before RPM begins. It would restrict remote therapeutic monitoring to established patients only. It would replace the current CPT billing codes with new, Medicare-specific HCPCS G-codes, giving CMS more direct control over how the codes are defined and priced going forward.
More than 200 organizations, spanning device makers, health systems, and patient groups, have asked CMS to delay finalizing the rule and work with the industry on proportionate, evidence-based guardrails rather than a blanket restriction on outsourced staffing (Alliance for Connected Care). Their argument is that the proposal, as written, would disrupt monitoring for more than a million Medicare beneficiaries and land hardest on small, rural, and safety-net practices, the same practices least able to hire monitoring staff in-house.
Here is my honest read as someone who has actually been through this from the device side.
Cardiowell built BT107, our blood pressure monitor, and took it through the FDA's 510(k) clearance process as a hypertension remote monitoring company. That process is not fast and it is not cheap, and it forces you to prove your device measures blood pressure the way you say it does before you can bill Medicare for anything built around it. I understand exactly why CMS is nervous about RPM. Billing for physiologic monitoring grew fast over the past several years, and a real share of that growth came from programs where nobody on staff ever actually looked at the data, where "monitoring" amounted to a vendor sending an invoice rather than a clinician catching a patient's blood pressure trending the wrong way.
CMS is right to want proof that monitoring is real. Requiring an initiating visit and tightening who can bill for clinical review work moves reimbursement closer to programs that are genuinely staffed and genuinely watched, which is good for patients and good for the companies that built their business on that being true from day one.
Where I would correct the record a little: outsourced clinical monitoring staff is mostly a large-organization tool. National RPM vendors use it to spread one call center across hundreds of practices, not something small independent clinics typically go out and buy on their own. Most of the small primary care and family medicine practices we work with were never running an outsourced monitoring desk in the first place.
Cardiowell's model has always been the opposite: we train the clinic's own staff to monitor their own patients, in-house, from day one. That is closer to what CMS's proposal is actually pushing the industry toward, and it is a big part of why we built the company this way.
The practices likely to feel real disruption are the ones currently leaning on a national outsourced vendor with no plan to bring monitoring in-house. For those clinics, this rule forces a real choice, and forcing it well means CMS pairing the restriction with a clear, workable path for smaller practices to build or borrow the staffing they need, not just a deadline. Getting monitoring closer to the people who actually know the patient is the right direction. Getting there without stranding small practices along the way is the part CMS still needs to get right.
The G-code switch is worth watching too. Once CMS owns the code definitions instead of routing changes through the CPT process, it becomes much easier to adjust RPM requirements again next year, and the year after that, without the multi-stakeholder review CPT changes usually go through. Companies building RPM programs for 2027 should plan for more policy movement ahead, not less.
A DEA prescribing deadline is closing in fast. Telemedicine prescribing of controlled substances is also facing a real deadline. The DEA submitted its final special registration rule to the White House Office of Information and Regulatory Affairs on August 25, with final action expected in November (Telehealth.org). The current flexibilities that let clinicians prescribe controlled substances via telemedicine without a prior in-person exam, in place since the pandemic, expire December 31, 2026.
That leaves a narrow window between publication and expiration for telehealth platforms and prescribers to adjust. The draft text stays confidential during OIRA review, so nobody outside the process has seen how the agency responded to more than 6,400 public comments. For hypertension and chronic care programs that lean on telemedicine visits alongside RPM, this is worth tracking even though it centers on prescribing rather than monitoring.
Cardiology gets its own mandatory payment model. Cardiology practices got a mandatory model this week. CMS placed more than 2,600 cardiologists in designated geographic areas on the mandatory participant list for its new Ambulatory Specialty Model for heart failure, which starts tracking quality measures on January 1, 2027, with payment adjustments beginning in 2029 (Cardiovascular Business). Practices will be scored on unplanned heart failure hospitalizations, use of guideline-directed medications, patient-reported outcomes, and total heart failure spending, including costs outside their direct control.
The model does not currently spell out a remote monitoring requirement. Cutting unplanned hospitalizations without one is hard, and blood pressure and weight trends remain two of the most practical early warning signs cardiology practices already have.
Clinical & Research
A landmark rural China trial ties blood pressure control directly to dementia prevention. The week's strongest clinical evidence came from rural China. The China Rural Hypertension Control Program, a cluster-randomized trial of 33,995 participants across 326 villages, found that an intensive blood pressure protocol, targeting systolic pressure under 130 and diastolic under 80 and delivered largely by trained non-physician community health workers, cut dementia risk by 15 percent over seven years compared with usual care (European Society of Cardiology). The intervention group's systolic pressure dropped an average of 17.6 points, versus 2.4 points in the usual-care group.
The trial was presented at ESC Congress in Munich on August 30. It stands as one of the largest and longest community-based hypertension trials to directly link blood pressure control to dementia prevention, and it did it without specialists, without expensive devices, and with health workers who are not physicians. That is a strong argument for treating consistent blood pressure control, measured regularly and acted on, as a dementia prevention strategy in its own right, not only a cardiovascular one.
An independent evaluator finds virtual kidney care has not proven itself. The Peterson Health Technology Institute assessed eight commercial virtual chronic kidney disease management platforms and found no consistent evidence that any of them slow kidney function decline or increase use of guideline-recommended medications compared with standard care (HIT Consultant). Five of the eight companies evaluated had published zero peer-reviewed clinical studies, despite each having raised more than $100 million.
The one benefit PHTI could document, a modest increase in patients starting dialysis on an optimal basis, affected fewer than 2 percent of patients a year and translated into gross savings of $53 to $401 per member annually, often less than the cost of running the program itself. CMS's own Kidney Care Choices demonstration lost Medicare $275 million in 2023.
Read alongside this week's RPM policy proposal, the message lines up: digital chronic care companies are entering a period where regulators, and now independent evaluators, expect proof of clinical impact, not just enrollment numbers and billing volume.
Also Worth a Glance
A hidden hormone disorder may explain a fifth of hypertension cases. Researchers from the University of Bristol, the University of Manchester, and the University of Bergen found that primary aldosteronism, a hormone disorder that can drive treatment-resistant high blood pressure, may affect as many as one in five people with hypertension, far more than standard single-point blood tests catch (SciTechDaily). Using a wearable hormone-sensing device on 60 patients, the team found that aldosterone levels surge and fall throughout the day and night, sometimes dropping below diagnostic thresholds during the exact blood draw window doctors typically use. The finding, published in Science Translational Medicine, reminds us that one normal lab value does not always rule out a secondary, treatable cause of high blood pressure.
The Thread
Pulling this week's stories together, a pattern shows up: everyone building around blood pressure and remote monitoring is being asked to show their work. Medicare wants proof that RPM monitoring is real and staffed, not just billed. PHTI wants proof that virtual chronic care changes outcomes, not just enrollment. Sky Labs and Oura are running large validation studies before making cuffless blood pressure claims, not after. And the China Rural Hypertension Control Program just proved, at a scale most companies will never reach, that consistent blood pressure control changes real outcomes years later. The bar for this industry keeps rising, which is exactly what should happen in a space built around people's hearts.
References
CART Blood Pressure Monitor Demonstrates Utility in BP Monitoring for AF and Heart Failure Patients. PR Newswire.
Ring type blood pressure monitor proves effective for heart failure patients. Vietnam Investment Review.
Apple advances health and fitness capabilities using Apple Intelligence and the most accurate heart rate sensing in a wearable. Apple Newsroom.
Apple starts preorders for Watch Series 12, Ultra 4 with new Health Sensing System. Ars Technica.
Oura Ring Files for IPO at $16B: Sensing Tech Behind 5M Members Explained. Tech Times.
CMS' Proposed Changes to Remote Monitoring Could Reshape Digital Healthcare Delivery. HIT Consultant.
Over 200 Organizations Urge CMS to Protect Remote Monitoring. Alliance for Connected Care.
DEA Telemedicine Special Registration Rule Enters Final Review. Telehealth.org.
Cardiologists scramble to prepare for mandatory heart failure payment model. Cardiovascular Business.
Long-term intensive blood-pressure control reduces dementia risk. European Society of Cardiology.
PHTI Assessment Finds Virtual CKD Management Fails to Slow Disease Progression or Cut Costs. HIT Consultant.
A Hidden Hormone Disorder May Be Driving Millions of High Blood Pressure Cases. SciTechDaily.